Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 825 matching trials from the live ClinicalTrials.gov search.
Conditions
X-Linked Retinitis Pigmentosa
Interventions
4D-125 IVT Injection, Observational
Biological · Other
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 5 more
Completed Not applicable Interventional Results available

Arm Rehabilitation Study After Stroke

NCT00871715
Conditions
Stroke, Brain Infarction, Brain Ischemia, Cerebral Infarction, Cerebrovascular Disorders
Interventions
Accelerated Skill Acquisition Program (ASAP), Dose-Equivalent Usual & Customary Care - DEUCC, Usual and Customary Care - UCC
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional

Sapphire 3 CTO Study

NCT06358508
Conditions
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Interventions
Sapphire 3 Coronary Dilatation Catheter
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Stanford, California • Torrance, California • Atlanta, Georgia + 5 more
Not yet recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Completed No phase listed Observational Results available

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016
Conditions
Otitis Media
Interventions
Tympanocentesis, Nose/throat swab, Observational
Procedure · Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 30 Months
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
7
States / cities
Penfield, New York • Rochester, New York
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
Completed Phase 1Phase 2 Interventional Results available

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

NCT02016235
Conditions
Dent Disease
Interventions
Phosphorus Supplement, Observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Biospecimens for Novel Research Uses

NCT03848962
Conditions
Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Interventions
Not listed
Lead sponsor
iSpecimen Inc
Industry
Eligibility
1 Month to 89 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Huntsville, Alabama • Lexington, Massachusetts
Conditions
Peyronie's Disease
Interventions
Subjects Previously Treated with AA4500
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more
Terminated Not applicable Interventional Results available

Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)

NCT00448448
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Brace, Observation
Device · Other
Lead sponsor
Stuart L. Weinstein, MD
Other
Eligibility
10 Years to 15 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Madera, California • Sacramento, California • San Diego, California + 18 more
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Completed Not applicable Interventional Results available

Omega Cuff for GERD Feasibility Study

NCT04793035
Conditions
GERD, Acid Reflux, Treatment
Interventions
Omega-Cuff
Device
Lead sponsor
Aplos Medical
Industry
Eligibility
22 Years to 74 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Los Angeles, California • Austin, Texas
Conditions
COVID, Neurologic Manifestations
Interventions
Observational study only
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 17 Years
Enrollment
3,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

NCT00678470
Conditions
Moderate to Severe Psoriasis
Interventions
Intralesional Alefacept
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Conditions
Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions
Observation Only
Other
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 79 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
Interventions
DETEC® Esterase
Diagnostic Test
Lead sponsor
Progenitec Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Conditions
Medication Non-adherence, Stent Thrombosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Lexington, Kentucky + 6 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Jet Injection Lidocaine for Blood Draws in Young Children

NCT01890642
Conditions
Pain
Interventions
J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose
Device · Other · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Months to 6 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Melanoma and Other Malignant Neoplasms of Skin
Interventions
Observational Study Only
Other
Lead sponsor
DermTech
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

NCT01569737
Conditions
Emergency Contraception
Interventions
ella
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational

PRecision Integrated Saturation Monitor

NCT07686341
Conditions
CHD - Congenital Heart Disease, Single Ventricle Heart Disease
Interventions
vital sign monitoring
Device
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
0 Months to 12 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Enrolling by invitation Not applicable Interventional

Tissue Growth Characterization for Cochlear Implant Users

NCT04320251
Conditions
Cochlear Implant
Interventions
cochlear implant revision surgery
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee